Abstract:
Thirty client-owned Pomeranians, 1 - 7 year- old with medial patellar luxation grade 3 and no other diseases are enrolled in this experiment. All dogs received physical examination, orthopedic examination, clinical scoring system, force platform gait analysis and blood collection by the same veterinarian before surgery and at day 1, 5 and 14 after surgery. After surgery of correction of medial patellar luxation, they are divided into 3 groups by random sampling. The first group received only Firocoxib (5 mg/kg once daily). The second group received only PCSO-524 (10 mg/kg, twice daily). The third group received Firocoxib (5 mg/kg, once daily) combining with PCSO-524 (10 mg/kg, twice daily). Treatment was finished at the end of the 2nd week. IL-1β and IL-6 concentration in serum are determined by commercially available canine ELISA kit. In conclusion, PCSO-524 can improve clinical signs in Pomeranian dogs after surgical correction of medial patellar luxation. The dogs in all groups of treatments had weight-bearing scores and gait data similar to standard score of normal dog in day 14 after surgery. However, PCSO-524 alone could not reduce blood level of inflammatory mediators when compared with NSAID, indicating that PCSO-524 did not have anti-inflammatory effect as good as NSAID in case of post-operative care of patellar luxation’s surgery.
